MSC-derived exosomes co-delivering anti-miR-221 and gemcitabine for inhibiting the proliferation of pancreatic cancer.

backgroudPancreatic ductal adenocarcinoma (PDAC) is among the most aggressive and lethal malignancies, with a dismal 5-year survival rate of approximately 4%. The majority of patients with pancreatic cancer have a poor response to traditional chemotherapy due to its disadvantages, such as drug resistance and biological toxicity. Therefore, a novel therapeutic methods should be developed to improve the efficacy of chemotherapy drugs in pancreatic cancer. In this study, we developed a co-delivery system utilizing exosomes as carriers to simultaneously encapsulate a miR-221-targeting antisense oligonucleotide (anti-miR-221) and gemcitabine(Gem) for treatment of PDAC.

methodsA lentiviral plasmid carrying the green fluorescent protein (GFP) reporter gene and anti-miR-221 was constructed and used to transfect the human umbilical cord blood mesenchymal stem cell line (MSCs). Exosomes secreted by the MSCs were purified using the ExoQuick reagent kit. Gemcitabine was loaded into the exosomes via sonication. After DAPI staining, Panc-1 cells were incubated with the exosomes, and uptake of exosomes loaded with anti-miR-221 and Gem by Panc-1 cells was confirmed using fluorescence microscopy. Experimental groups were as follows: blank exosomes (blank-exo group); exosomes loaded with anti-miR-221 (exo-221 group); exosomes loaded with Gem (exo-Gem group); Gemcitabine monotherapy (Gem group); and exosomes co-loaded with anti-miR-221 and Gem (exo-Gem-221 group).The effects of drug delivery system on Panc-1 cell proliferation were assessed using the CCK-8 assay, and miR-221 expression levels in Panc-1 cells were measured via RT-PCR. For the study in vivo, treatments were administered via intratumoral injection into a nude mouse model with subcutaneous Panc-1 xenografts. The tumor volume and weight were measured to calculate the tumor inhibition rate. miR-221 expression in tumor tissues was detected by RT-PCR. Protein expression levels of VEGF and Caspase-3 in tumor tissues were evaluated by immunohistochemistry. Liver and kidney tissues from the mice were collected, subjected to H&E staining, and examined under a light microscope for pathological changes.

resultsIn both in vitro and in vivo experiments, miR-221 levels were significantly lower in the exo-221 and exo-Gem-221 groups compared to the blank-exo group (P < 0.01), demonstrating that exosome-delivered anti-miR-221 effectively silenced miR-221 expression in pancreatic cancer cells. The CCK-8 assay showed that cell viability was significantly reduced in the exo-221, exo-Gem, and Gem monotherapy groups compared to the blank-exo group (P < 0.05). Furthermore, the exo-Gem-221 group exhibited a more pronounced decrease in cell viability compared to the exo-Gem, exo-221, and Gem monotherapy groups (P < 0.01). Animal experiments revealed that tumor volume and weight were significantly decreased in the exo-221, exo-Gem, and Gem monotherapy groups compared to the blank-exo group (P < 0.05). The exo-Gem-221 group showed a more significant reduction in tumor volume and weight and a higher tumor inhibition rate compared to the exo-221, exo-Gem, and Gem monotherapy groups (P < 0.01). Immunohistochemistry indicated that protein levels of Caspase-3 were significantly increased, while VEGF levels were significantly decreased, in the exo-221, exo-Gem, and Gem monotherapy groups compared to the blank-exo group (P < 0.05). These changes were even more pronounced in the exo-Gem-221 group compared to the exo-221, exo-Gem, and Gem monotherapy groups (P < 0.01). H&E staining of liver and kidney tissues from nude mice showed hepatic sinusoid atrophy and disordered hepatic plate arrangement in the liver, as well as glomerular shrinkage and peri-glomerular cell necrosis in the kidneys, only in the Gem monotherapy group. No significant pathological changes were observed in the liver or kidney tissues of the other groups.

conclusionsExosomes derived from MSCs and co-loaded with anti-miR-221 and Gemcitabine significantly inhibit the proliferation of pancreatic cancer. This combined antitumor effect is superior to that of exo-221, exo-Gem, or Gemcitabine monotherapy. Furthermore, this approach demonstrates low liver and kidney toxicity, suggesting it may be a safe and effective method for treating pancreatic cancer.